Organovo Up 6% Pre-Bell

Shares of Organovo were up pre-market Tuesday after the company said it will present first preclinical data on its 3D bioprinted human liver tissue at the TERMIS-Americas Meeting in San Diego, California.

The company, which is developing novel therapeutic tissues for direct surgical implantation using its 3D bioprinting technology, said the data will show survival and sustained fuctionality of the human liver tissue when implanted into animal models.

Organovo added it plans to submit an investigational new drug application to the Food and Drug Administration for its therapeutic liver tissue in the next three to five years.

Leave a Comment